Immunebridge Stem Cell Expansion Patent - Fluorene Derivatives
Summary
The European Patent Office published patent EP3700334A1 granted to Immunebridge Inc. covering compositions and methods for expanding hematopoietic stem cells using fluorene derivatives. The patent names inventors Jesse Cotari, Timothy Webb, and Zhan Wang, with broad IPC classifications spanning chemical compounds (C07C, C07D), pharmaceutical preparations (A61K), and therapeutic applications (A61P). The patent is designated across 32 European member states.
What changed
The EPO granted Immunebridge Inc. patent EP3700334A1 for compositions and methods of making expanded hematopoietic stem cells using fluorene derivatives. The patent application, filed with multiple IPC classifications covering chemical compounds and therapeutic applications, has been published with designation across 32 European countries including Germany, France, UK, Italy, Spain, and other EU member states.
For biotechnology and pharmaceutical companies engaged in stem cell research or cellular therapy development, this patent establishes intellectual property protection that may affect research directions and product development strategies. Companies developing hematopoietic stem cell therapies or related expansion technologies should conduct freedom-to-operate analyses and consider potential licensing discussions with Immunebridge to avoid infringement risks in European markets.
What to do next
- Monitor patent portfolio for Freedom to Operate considerations
- Review licensing opportunities for stem cell expansion technology
- Assess competitive landscape for similar fluorene-based stem cell compositions
Archived snapshot
Apr 8, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
COMPOSITIONS AND METHODS OF MAKING EXPANDED HEMATOPOIETIC STEM CELLS USING DERIVATIVES OF FLUORENE
Publication EP3700334A1 Kind: A1 Apr 01, 2026
Applicants
Immunebridge Inc.
Inventors
COTARI, Jesse, WEBB, Timothy, WANG, Zhan
IPC Classifications
C07C 215/70 20060101AFI20210616BHEP A01K 67/027 20060101ALI20210616BHEP A61K 49/00 20060101ALI20210616BHEP A61P 35/00 20060101ALI20210616BHEP C07C 35/52 20060101ALI20210616BHEP A61K 35/28 20150101ALI20210616BHEP C07C 49/675 20060101ALI20210616BHEP C07C 49/697 20060101ALI20210616BHEP C07C 69/16 20060101ALI20210616BHEP C07C 69/28 20060101ALI20210616BHEP C07C 225/22 20060101ALI20210616BHEP C07C 233/25 20060101ALI20210616BHEP C07C 233/33 20060101ALI20210616BHEP C07C 233/43 20060101ALI20210616BHEP C07C 237/38 20060101ALI20210616BHEP C07C 251/44 20060101ALI20210616BHEP C07C 255/47 20060101ALI20210616BHEP C07C 271/30 20060101ALI20210616BHEP C07C 275/32 20060101ALI20210616BHEP C07D 309/08 20060101ALI20210616BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Related changes
Get daily alerts for ChangeBridge: EPO Bulletin - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from EPO.
The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ChangeBridge: EPO Bulletin - Therapeutics (A61P) publishes new changes.